|
Mick Fellows PhD
Senior Director Biopharma Cell Therapy Safety
AstraZeneca
USA
|
Dr Mick Fellows, Senior Director of Biopharma Cell Therapy Safety at AstraZeneca in Cambridge UK.
Mick earned his Ph.D in Pharmacology and Toxicology investigating topoisomerase II inhibition at Liverpool University.
In the late 1980’s he joined Covance, where he developed a range of in vitro and in vivo genetox assays, becoming an authority on in vitro mutagenesis and phototoxicity.
In 2001, he joined AstraZeneca, initially as a genetic toxicologist. However, over the last decade, Mick’s research has focused on AstraZeneca’s advanced medicine safety platforms, including genome editing and modified RNA therapies. Mick’s current role is as the AZ Biopharma cell and regenerative medicine safety lead.
Mick had the honour of serving as the president of the United Kingdom Environmental Mutagen Society and has worked on and chaired several international workgroups; including OECD, EFPIA and ICH. In 2022 Mick was elected Industrial co-chair of HESI CT-TRACS.
Mick earned his Ph.D in Pharmacology and Toxicology investigating topoisomerase II inhibition at Liverpool University.
In the late 1980’s he joined Covance, where he developed a range of in vitro and in vivo genetox assays, becoming an authority on in vitro mutagenesis and phototoxicity.
In 2001, he joined AstraZeneca, initially as a genetic toxicologist. However, over the last decade, Mick’s research has focused on AstraZeneca’s advanced medicine safety platforms, including genome editing and modified RNA therapies. Mick’s current role is as the AZ Biopharma cell and regenerative medicine safety lead.
Mick had the honour of serving as the president of the United Kingdom Environmental Mutagen Society and has worked on and chaired several international workgroups; including OECD, EFPIA and ICH. In 2022 Mick was elected Industrial co-chair of HESI CT-TRACS.